Immunotherapeutic Options for Epstein-Barr Virus-associated Lymphoproliferative Disease Following Transplantation

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2010 Sep 30

PMID 20874650

Citations 6

Authors

Donald R Shaffer

Cliona M Rooney

Stephen Gottschalk

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development of early detection methods, such as serial measurements of EBV-DNA load in the peripheral blood of transplant recipients. Immunotherapeutic interventions for EBV-LPD include reduction of immunosuppression, CD20 monoclonal antibodies (rituximab) as monotherapy or in conjunction with chemotherapy, and adoptive immunotherapy with EBV-specific T cells. Pre-emptive immunotherapeutic interventions can prevent the development of EBV-LPD. As monotherapy, immunotherapy is effective in inducing remissions of EBV-LPD with low-risk features. For high-risk disease, combining immunotherapy with conventional therapies has led to superior outcomes. Current challenges consist of risk stratifying patients so that patients receive the most efficacious therapy without suffering from unwanted side effects.

Citing Articles

Insights into the interplay between Epstein-Barr virus (EBV) and multiple sclerosis (MS): A state-of-the-art review and implications for vaccine development.

Mohammadzamani M, Kazemzadeh K, Chand S, Thapa S, Ebrahimi N, Yazdan Panah M Health Sci Rep. 2024; 7(2):e1898.

PMID: 38361801 PMC: 10867693. DOI: 10.1002/hsr2.1898.

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.

Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H J Clin Invest. 2023; 133(12).

PMID: 37159273 PMC: 10266790. DOI: 10.1172/JCI163548.

Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Nada A, Jetton J Pediatr Nephrol. 2020; 36(8):2227-2255.

PMID: 33245421 DOI: 10.1007/s00467-020-04800-3.

Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.

Kondo S, Tanimoto K, Yamada K, Yoshimoto G, Suematsu E, Fujisaki T Virchows Arch. 2013; 462(4):399-407.

PMID: 23494713 DOI: 10.1007/s00428-013-1389-1.

Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia.

Sugimoto-Sekiguchi H, Tashiro H, Shirasaki R, Arai T, Yamamoto T, Oka Y Case Rep Gastrointest Med. 2012; 2012:395801.

PMID: 23050175 PMC: 3461615. DOI: 10.1155/2012/395801.

References

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

Meij P, van Esser J, Niesters H, van Baarle D, Miedema F, Blake N . Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003; 101(11):4290-7. DOI: 10.1182/blood-2002-10-3001. View

Verschuuren E, Stevens S, van Imhoff G, Middeldorp J, de Boer C, Koeter G . Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002; 73(1):100-4. DOI: 10.1097/00007890-200201150-00019. View

Dharnidharka V, Ho P, Stablein D, Harmon W, Tejani A . Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 2002; 6(5):396-9. DOI: 10.1034/j.1399-3046.2002.00021.x. View

Rooney C, Loftin S, Holladay M, Brenner M, Krance R, Heslop H . Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995; 89(1):98-103. DOI: 10.1111/j.1365-2141.1995.tb08904.x. View

McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D . Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant. 2000; 24(11):1253-8. DOI: 10.1038/sj.bmt.1702052. View

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003; 3(1):35-45. DOI: 10.1038/nrc971. View

Knight J, Tsodikov A, Cibrik D, Ross C, Kaminski M, Blayney D . Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009; 27(20):3354-62. DOI: 10.1200/JCO.2008.20.0857. View

Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S . Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010; 115(14):2960-70. DOI: 10.1182/blood-2009-08-236356. View

10.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

11.

Faro A . Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Springer Semin Immunopathol. 1998; 20(3-4):425-36. DOI: 10.1007/BF00838053. View

12.

Nash R, Dansey R, Storek J, Georges G, Bowen J, Holmberg L . Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant. 2003; 9(9):583-91. PMC: 2956744. DOI: 10.1016/s1083-8791(03)00228-3. View

13.

Haque T, Taylor C, Wilkie G, Murad P, Amlot P, Beath S . Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 2001; 72(8):1399-402. DOI: 10.1097/00007890-200110270-00012. View

14.

Gustafsson A, Levitsky V, Zou J, Frisan T, Dalianis T, Ljungman P . Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000; 95(3):807-14. View

15.

Rooney C, Smith C, Ng C, Loftin S, Sixbey J, Gan Y . Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998; 92(5):1549-55. View

16.

OReilly R, Small T, Papadopoulos E, Lucas K, LACERDA J, Koulova L . Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol. 1998; 20(3-4):455-91. DOI: 10.1007/BF00838055. View

17.

Introna M, Barbui A, Bambacioni F, Casati C, Gaipa G, Borleri G . Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000; 11(4):611-20. DOI: 10.1089/10430340050015798. View

18.

Weinstock D, Ambrossi G, Brennan C, Kiehn T, Jakubowski A . Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006; 37(6):539-46. DOI: 10.1038/sj.bmt.1705289. View

19.

Pule M, Savoldo B, Myers G, Rossig C, Russell H, Dotti G . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-70. PMC: 2749734. DOI: 10.1038/nm.1882. View

20.

Choquet S, Oertel S, Leblond V, Riess H, Varoqueaux N, Dorken B . Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007; 86(8):599-607. DOI: 10.1007/s00277-007-0298-2. View